Form 4: Enanta Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Tara Lynn Kieffer, Chief Product Strategy Officer of Enanta Pharmaceuticals, sold 7,266 shares of common stock on June 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 17, 2024, Tara Lynn Kieffer, the Chief Product Strategy Officer of Enanta Pharmaceuticals, sold 7,266 shares of the company's common stock.
• The sale was executed at a weighted-average price of $12.33 per share, with individual transactions ranging from $12.20 to $12.54.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted in March 2024.
• Following the reported transaction, Kieffer directly owns 32,341 shares of Enanta Pharmaceuticals.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within the range to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by an executive under a pre-arranged trading plan, which is neither particularly positive nor negative.

Industry Context

Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of acting on insider information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates